Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Liabilities: 2010-2024

Historic Total Liabilities for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $54.2 million.

  • OptimizeRx's Total Liabilities fell 527.46% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year decrease of 527.46%. This contributed to the annual value of $54.2 million for FY2024, which is 466.55% down from last year.
  • According to the latest figures from FY2024, OptimizeRx's Total Liabilities is $54.2 million, which was down 466.55% from $56.8 million recorded in FY2023.
  • Over the past 5 years, OptimizeRx's Total Liabilities peaked at $56.8 million during FY2023, and registered a low of $8.5 million during FY2022.
  • In the last 5 years, OptimizeRx's Total Liabilities had a median value of $10.4 million in 2020 and averaged $27.9 million.
  • In the last 5 years, OptimizeRx's Total Liabilities plummeted by 1207.88% in 2020 and then soared by 56531.95% in 2023.
  • Over the past 5 years, OptimizeRx's Total Liabilities (Annual) stood at $10.4 million in 2020, then decreased by 7.23% to $9.6 million in 2021, then decreased by 11.09% to $8.5 million in 2022, then surged by 565.32% to $56.8 million in 2023, then fell by 4.67% to $54.2 million in 2024.
  • Its Total Liabilities was $54.2 million in FY2024, compared to $56.8 million in FY2023 and $8.5 million in FY2022.